Role of the Apparent Diffusion Coefficient as a Predictor of Tumor Progression in Patients with Chordoma

References

1. 1.↵
   2. Fletcher CD,
   3. Bridge JA,
   4. Hogendoorn P, et al

   . WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013
2. 2.↵
   2. Chugh R,
   3. Tawbi H,
   4. Lucas DR, et al

   . Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007;12:1344–50 doi:10.1634/theoncologist.12-11-1344 pmid:18055855

   Abstract/FREE Full Text
3. 3.↵
   2. Müller U,
   3. Kubik-Huch RA,
   4. Ares C, et al

   . Is there a role for conventional MRI and MR diffusion-weighted imaging for distinction of skull base chordoma and chondrosarcoma? Acta Radiol 2016;57:225–32 doi:10.1177/0284185115574156 pmid:25722460

   CrossRefPubMed
4. 4.↵
   2. Yeom KW,
   3. Lober RM,
   4. Mobley BC, et al

   . Diffusion-weighted MRI: distinction of skull base chordoma from chondrosarcoma. AJNR Am J Neuroradiol 2013;34:1056–61, S1 doi:10.3174/ajnr.A3333 pmid:23124635

   Abstract/FREE Full Text
5. 5.↵
   2. Hanna SA,
   3. Tirabosco R,
   4. Amin A, et al

   . Dedifferentiated chordoma: a report of four cases arising ‘de novo.’ J Bone Joint Surg Br 2008;90:652–56 pmid:18450635

   PubMed
6. 6.↵
   2. Ailon T,
   3. Torabi R,
   4. Fisher CG, et al

   . Management of locally recurrent chordoma of the mobile spine and sacrum: a systematic review. Spine (Phila Pa 1976) 2016;41(Suppl 20):S193–98 doi:10.1097/BRS.0000000000001812 pmid:27753782

   CrossRefPubMed
7. 7.↵
   2. Gokaslan ZL,
   3. Zadnik PL,
   4. Sciubba DM, et al

   . Mobile spine chordoma: results of 166 patients from the AOSpine Knowledge Forum Tumor database. J Neurosurg Spine 2016;24:644–51 doi:10.3171/2015.7.SPINE15201 pmid:26682601

   CrossRefPubMed
8. 8.↵
   2. Boriani S,
   3. Saravanja D,
   4. Yamada Y, et al

   . Challenges of local recurrence and cure in low grade malignant tumors of the spine. Spine (Phila Pa 1976) 2009;34:S48–57 doi:10.1097/BRS.0b013e3181b969ac pmid:19829277

   CrossRefPubMed
9. 9.↵
   2. Boriani S,
   3. Bandiera S,
   4. Biagini R, et al

   . Chordoma of the mobile spine: fifty years of experience. Spine (Phila Pa 1976) 2006;31:493–503 doi:10.1097/01.brs.0000200038.30869.27 pmid:16481964

   CrossRefPubMedWeb of Science
10. 10.↵
    2. York JE,
    3. Kaczaraj A,
    4. Abi-Said D, et al

    . Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 1999;44:74–79; discussion 79–80 doi:10.1097/00006123-199901000-00041 pmid:9894966

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Chen KW,
    3. Yang HL,
    4. Lu J, et al

    . Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord 2010;48:166–71 doi:10.1038/sc.2009.95 pmid:19621022

    CrossRefPubMed
12. 12.↵
    2. Hulen CA,
    3. Temple HT,
    4. Fox WP, et al

    . Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am 2006;88:1532–39 pmid:16818979

    Abstract/FREE Full Text
13. 13.↵
    2. Pennicooke B,
    3. Laufer I,
    4. Sahgal A, et al

    . Safety and local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. Spine (Phila Pa 1976) 2016;41(Suppl 20):S186–92 doi:10.1097/BRS.0000000000001831 pmid:27509195

    CrossRefPubMed
14. 14.↵
    2. Eisenhauer EA,
    3. Therasse P,
    4. Bogaerts J, et al

    . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47 doi:10.1016/j.ejca.2008.10.026 pmid:19097774

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Si MJ,
    3. Wang CS,
    4. Ding XY, et al

    . Differentiation of primary chordoma, giant cell tumor and schwannoma of the sacrum by CT and MRI. Eur J Radiol 2013;82:2309–15 doi:10.1016/j.ejrad.2013.08.034 pmid:24035342

    CrossRefPubMed
16. 16.↵
    2. Kabolizadeh P,
    3. Chen YL,
    4. Liebsch N, et al

    . Updated outcome and analysis of tumor response in mobile spine and sacral chordoma treated with definitive high-dose photon/proton radiation therapy. Int J Radiat Oncol Biol Phys 2017;97:254–62 doi:10.1016/j.ijrobp.2016.10.006 pmid:27986348

    CrossRefPubMed
17. 17.↵
    2. Choe J,
    3. Lee SM,
    4. Lim S, et al

    . Doubling time of thymic epithelial tumours on CT: correlation with histological subtype. Eur Radiol 2017;27:4030–36 doi:10.1007/s00330-017-4795-y pmid:28332015

    CrossRefPubMed
18. 18.↵
    2. Zukotynski KA,
    3. Vajapeyam S,
    4. Fahey FH, et al

    . Correlation of 18F-FDG PET and MRI apparent diffusion coefficient histogram metrics with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med 2017;58:1264–69 doi:10.2967/jnumed.116.185389 pmid:28360212

    Abstract/FREE Full Text
19. 19.↵
    2. Bettegowda C,
    3. Yip S,
    4. Lo SL, et al

    ; AOSpine Knowledge Forum Tumor. Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival. Neuro Oncol 2017;19:405–13 doi:10.1093/neuonc/now156 pmid:27663388

    CrossRefPubMed
20. 20.↵
    2. Park L,
    3. Delaney TF,
    4. Liebsch NJ, et al

    . Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006;65:1514–21 doi:10.1016/j.ijrobp.2006.02.059 pmid:16757128

    CrossRefPubMed
21. 21.↵
    2. Kayani B,
    3. Sewell MD,
    4. Tan KA, et al

    . Prognostic factors in the operative management of sacral chordomas. World Neurosurg 2015;84:1354–61 doi:10.1016/j.wneu.2015.06.030 pmid:26115803

    CrossRefPubMed
22. 22.↵
    2. Han X,
    3. Suo S,
    4. Sun Y, et al

    . Apparent diffusion coefficient measurement in glioma: influence of region-of-interest determination methods on apparent diffusion coefficient values, interobserver variability, time efficiency, and diagnostic ability. J Magn Reson Imaging 2017;45:722–30 doi:10.1002/jmri.25405 pmid:27527072

    CrossRefPubMed
23. 23.↵
    2. Kayani B,
    3. Sewell MD,
    4. Hanna SA, et al

    . Prognostic factors in the operative management of dedifferentiated sacral chordomas. Neurosurgery 2014;75:269–75; discussion 275 doi:10.1227/NEU.0000000000000423 pmid:24867206

    CrossRefPubMed
24. 24.↵
    2. Kim SC,
    3. Cho W,
    4. Chang UK, et al

    . Two cases of dedifferentiated chordoma in the sacrum. Korean J Spine 2015;12:230–34 doi:10.14245/kjs.2015.12.3.230 pmid:26512292

    CrossRefPubMed
25. 25.↵
    2. Makek M,
    3. Leu HJ

    . Malignant fibrous histiocytoma arising in a recurrent chordoma: case report and electron microscopic findings. Virchows Arch A Pathol Anat Histol 1982;397:241–50 doi:10.1007/BF00496567 pmid:6297147

    CrossRefPubMed
26. 26.↵
    2. Halpern J,
    3. Kopolovic J,
    4. Catane R

    . Malignant fibrous histiocytoma developing in irradiated sacral chordoma. Cancer 1984;53:2661–62 pmid:6326989

    CrossRefPubMed
27. 27.↵
    2. Fukuda T,
    3. Aihara T,
    4. Ban S, et al

    . Sacrococcygeal chordoma with a malignant spindle cell component: a report of two autopsy cases with a review of the literature. Acta Pathol Jpn 1992;42:448–53 pmid:1502905

    PubMed
28. 28.↵
    2. Hruban RH,
    3. May M,
    4. Marcove RC, et al

    . Lumbo-sacral chordoma with high-grade malignant cartilaginous and spindle cell components. Am J Surg Pathol 1990;14:384–89 doi:10.1097/00000478-199004000-00012 pmid:1690955

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Ruosi C,
    3. Colella G,
    4. Di Donato SL, et al

    . Surgical treatment of sacral chordoma: survival and prognostic factors. Eur Spine J 2015;24(Suppl 7):912–17 doi:10.1007/s00586-015-4276-4 pmid:26458933

    CrossRefPubMed
30. 30.↵
    2. Kayani B,
    3. Hanna SA,
    4. Sewell MD, et al

    . A review of the surgical management of sacral chordoma. Eur J Surg Oncol 2014;40:1412–20 doi:10.1016/j.ejso.2014.04.008 pmid:24793103

    CrossRefPubMed
31. 31.↵
    2. Hong X,
    3. Liu L,
    4. Wang M, et al

    . Quantitative multiparametric MRI assessment of glioma response to radiotherapy in a rat model. Neuro Oncol 2014;16:856–67 doi:10.1093/neuonc/not245 pmid:24366911

    CrossRefPubMed
32. 32.↵
    2. Morse DL,
    3. Galons JP,
    4. Payne CM, et al

    . MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed 2007;20:602–14 doi:10.1002/nbm.1127 pmid:17265424

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Chenevert TL,
    3. Stegman LD,
    4. Taylor JM, et al

    . Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029–36 doi:10.1093/jnci/92.24.2029 pmid:11121466

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Jordan BF,
    3. Runquist M,
    4. Raghunand N, et al

    . Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005;7:475–85 doi:10.1593/neo.04628 pmid:15967100

    CrossRefPubMed
35. 35.↵
    2. Imai R,
    3. Kamada T,
    4. Araki N

    . Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases. Int J Radiat Oncol Biol Phys 2016;95:322–27 doi:10.1016/j.ijrobp.2016.02.012 pmid:27084649

    CrossRefPubMed
36. 36.↵
    2. Uhl M,
    3. Welzel T,
    4. Jensen A, et al

    . Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma. Strahlenther Onkol 2015;191:597–603 doi:10.1007/s00066-015-0825-3 pmid:25737378

    CrossRefPubMed
37. 37.↵
    2. Choy W,
    3. Terterov S,
    4. Kaprealian TB, et al

    . Predictors of recurrence following resection of intracranial chordomas. J Clin Neurosci 2015;22:1792–96 doi:10.1016/j.jocn.2015.05.024 pmid:26209919

    CrossRefPubMed